# Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

> **NCT04325425** · PHASE2 · RECRUITING · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 218 (estimated)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** FOLFOXIRI Protocol
- **DRUG:** Cisplatin injection

## Key facts

- **NCT ID:** NCT04325425
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-01
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2025-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325425, "Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04325425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*